FRI0185 Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs - a network meta-analysis

Background Tofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy in rheumatoid arthritis (RA). Objectives A network meta-analysis to evaluate the efficacy and safety of tofacitinib 5 and 10 mg BID relat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.375
Hauptverfasser:	Vieira, M.C., Wallenstein, G.V., Bradley, J.D., Gruben, D., Koncz, T., Zwillich, S.H., Jansen, J.P.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!